Drug Trial Radar · NCT01633112
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Last checked: Nov 20, 2026Latest source record: May 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,064
Actual
Start
Aug 9, 2012
Primary completion
Apr 30, 2018
Study completion Apr 30, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
fingolimodDrug
capsule
glatiramer acetateDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Annualized Relapse RateTime frame: up to 12 months
Locations
130 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Loveland, Colorado
Novartis Investigative Site
Fairfield, Connecticut
Novartis Investigative Site
Newark, Delaware
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Naples, Florida
Novartis Investigative Site
New Port Richey, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Ormond Beach, Florida
Novartis Investigative Site
Pompano Beach, Florida
Novartis Investigative Site
Ponte Vedra Beach, Florida
Novartis Investigative Site
Port Charlotte, Florida
Novartis Investigative Site
Sarasota, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Vero Beach, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Elk Grove Village, Illinois
Novartis Investigative Site
Evanston, Illinois
Novartis Investigative Site
Flossmoor, Illinois
Novartis Investigative Site
Northbrook, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
West Des Moines, Iowa
Novartis Investigative Site
Kansas City, Kansas
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
Louisville, Kentucky
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.